PHIOGEN Inc.
PHIOGEN is a preclinical-stage biotechnology company developing bacteriophage-based approaches for drug-resistant and recurrent bacterial infections. Its development work combines phage discovery and selection, directed evolution, human-relevant infection models, formulation, and preclinical testing. The company is also exploring immune responses associated with phage therapy.
Industries
N/A
PHIOGEN Inc.
1840 Dynamic Way, Rm 270, Houston, Texas 77030, USA
PHIOGEN Inc. is currently seeking investment
PHIOGEN Inc. is seeking a series-a investment in the range of
Expertise Areas
- Bacteriophage therapeutics
- Antimicrobial-resistant bacterial infections
- Phage biology and evolution
- Bacterial pathogenesis
Key Technologies
- Bacteriophage isolation and screening
- Genome sequencing and annotation
- Directed evolution
- Stem-cell-derived 3D culture models
Key People
Chief Executive Officer
Clinical Operations Manager
Bioinformaticist
Head of Finance
Associate Scientist
Associate Scientist
Chief Executive Officer
Clinical Operations Manager
Bioinformaticist
Head of Finance
Associate Scientist
Associate Scientist
News & Updates
PHIOGEN was named among the Top 10 Most Promising Life Science Companies at the Texas Life Science Forum.
PHIOGEN, Baylor College of Medicine, and LillixBio announced a collaboration using AI-supported antigen mapping and laboratory validation to study immune responses following phage therapy, initially targeting E. coli.
PHIOGEN announced support from CARB-X for a project targeting E. coli infections using bacteriophages.
PHIOGEN was named among the Top 10 Most Promising Life Science Companies at the Texas Life Science Forum.
PHIOGEN, Baylor College of Medicine, and LillixBio announced a collaboration using AI-supported antigen mapping and laboratory validation to study immune responses following phage therapy, initially targeting E. coli.
PHIOGEN announced support from CARB-X for a project targeting E. coli infections using bacteriophages.